Clinical characteristics | RA (Mean ± SD) | Control (Mean ± SD) | p | JIA (Mean ± SD) | Control (Mean ± SD) | p |
---|---|---|---|---|---|---|
Sex ratio (Female/Male) | 3.63 (842/232) | 3.47 (1314/378) | 0.17 | 4.56 (178/39) | 4.72 (312/66) | 0.89 |
Age (years) | 41.7 ± 11.6 | 39.6 ± 13.2 | 0.75 | 6.3 ± 3.1 | 6.7 ± 2.5 | 0.75 |
Onset age, years | 49.5 ± 7.9 | – | – | 7.5 ± 4.9 | – | – |
Bone erosions n (%) | 421 (39.1%) | – | – | 46 (21.3%) | – | – |
Shared epitope | 467 (43.5%) | – | – | 79 (36.4%) | – | – |
DAS28 | 4.7 ± 1.3 | – | – | 3.4 ± 1.1 | – | – |
ESR (mm/h) (0–10 mm/h) | 33.2 ± 12.5 | 4.5 ± 2.2 | <0.001 | 34.5 ± 19.3 | 4.3 ± 2.4 | <0.001 |
CRP (mg/l) (0.8–8 mg/l) | 25.8 ± 12.2 | 4.9 ± 1.3 | <0.001 | 19.3 ± 37.5 | 3.77 ± 1.4 | <0.001 |
IgA mg/mL (0.71–3.35 mg/mL) | 12.2 ± 2.7 | 2.88 ± 1.4 | <0.001 | 10.2 ± 2.4 | 2.59 ± 1.7 | <0.001 |
IgG mg/mL (7.6–16.6 mg/mL) | 45.7 ± 5.4 | 10.3 ± 4.1 | <0.001 | 29.6 ± 5.1 | 9.7 ± 1.3 | <0.001 |
IgM mg/mL (0.48–2.12 mg/mL) | 6.6 ± 1.3 | 1.78 ± 2.1 | <0.001 | 5.4 ± 1.7 | 1.88 ± 1.02 | <0.001 |
RF+, % | 826 (76.9%) | 0 (0%) | Â | 37 (16.9%) | 0 (0%) | Â |
CCP+, % | 766 (71.3%) | 0 (0%) | Â | 33 (15.4%) | 0 (0%) | Â |